Zm323881 hydrochloride

The effects of the inhibition of VEGF signaling on cell viability and apoptosis were investigated using a selective inhibitor of VEGFR2 (ZM323881 hydrochloride, Tocris, Bristol, UK) diluted to 1 μM in modified DMEM. Control cells were treated with the same concentration of the VEGFR2 inhibitor diluent alone (DMSO). Cells were treated just before light exposure. Viability and apoptosis were assessed 6 h after the end of light exposure using the ApoLive-Glo^™ Multiplex Assay (Promega) as previously described [45 (link)].

Erlotinib hydrochloride (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy) quinazolin-4-amine; C22H23N3O4•HCl) was obtained from LC laboratories (Woburn, MA, USA), reconstituted in Dimethyl Sulfoxide (DMSO) at a concentration of 20 mM, and then stored in aliquots of 20 µL at −20 °C. ZM 323,881 hydrochloride (5-((7-Benzyloxyquinazolin-4-yl)amino)-4-fluoro-2-methylphenol hydrochloride), a selective inhibitor of VEGFR2, was obtained from Tocris Bioscience, a Bio-Techne brand (Minneapolis, MN, USA) [36 (link)], reconstituted in DMSO at a concentration of 1 mM, and then stored in aliquots at −20 °C. Epidermal Growth Factor (EGF) was obtained from Peprotech (Rocky Hill, NJ, USA), reconstituted in PBS to obtain a concentration of 15 ng/µL, and aliquots were stored at −20 °C.